Newsfeeds Archive - Page 2 of 5

2 minute read

Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response

April 1, 10:52 AM

Disc Medicine releases AURORA Phase 2 study data on bitopertin for Erythropoietic Protoporphyria. Significant reductions in PPIX levels and improvements in phototoxic reactions observed with bitopertin treatment.

DISC

3 minute read

Disc Reports Topline Results From Phase 2 AURORA Study Of Bitopertin In Patients With Erythropoietic Protoporphyria; Met Primary Endpoint, Demonstrating Dose-Dependent, Statistically Significant Reductions In Protoporphyrin IX; Improved Measures Of Lig…

By Benzinga Newsdesk

April 1, 8:13 AM

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light tolerance, including

IRON

3 minute read

Disc Medicine Appoints Industry Executive Jean Franchi As Chief Financial Officer, And Promotes Jonathan Yu To Chief Operating Officer

By Benzinga Newsdesk

February 7, 9:05 AM

Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage companiesJonathan Yu,

IRON

2 minute read

Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday

By Avi Kapoor

December 12, 11:13 AM

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Tuesday.

APPS

4 minute read

Disc Presents Initial Data From Ongoing Phase 1b/2 Trial Of DISC-0974 In Patients With Myelofibrosis And Anemia At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 11, 1:03 PM

Substantial, dose-dependent reductions in serum hepcidin and increases in serum ironHematologic response demonstrated by increased hemoglobin levels and reduction in transfusion burdenDISC-0974 was generally

IRON

3 minute read

Disc Medicine Announces Multiple Presentations Across Portfolio At The 65th American Society Of Hematology Annual Meeting And Key Program Updates

By Benzinga Newsdesk

November 2, 9:11 AM

Completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP)Oral presentation at ASH meeting of updated interim data from BEACON, including a preliminary analysis of

IRON

2 minute read

Disc Medicine Announces Planned Departure Of Chief Financial Officer Joanne Bryce; Co Initiated A Search To Fill The Position. Ms. Bryce Plans To Remain With The Co And Oversee Her Current Responsibilities Until A Successor Has Been Identified

By Happy Mohamed

October 23, 9:17 AM

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,

IRON

1 minute read

News

5 Value Stocks To Watch In The Healthcare Sector

By Benzinga Insights

September 4, 10:44 AM

Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies…

APRE

2 minute read

Analyst Ratings

Where Disc Medicine Stands With Analysts

By Benzinga Insights

August 14, 10:00 AM

Within the last quarter, Disc Medicine (NASDAQ:IRON) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

IRON

4 minute read

Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

June 29, 1:52 PM

Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash.

ACHR